Related Experiment Video
Updated: Aug 20, 2026
Minimally Invasive Murine Laryngoscopy for Close-Up Imaging of Laryngeal Motion During Breathing and Swallowing
Published on: December 1, 2023
Auditory effects after organ preservation protocol for laryngeal/hypopharyngeal carcinomas
Patricia Helena Pecora Liberman1, Christiane Schultz, M Valéria Schmidt Goffi Gomez
1Department of Audiology, Hospital do Câncer A.C. Camargo, São Paulo, Brazil.
Objective:
To investigate the prevalence of hearing loss after concomitant radiochemotherapy in patients enrolled in a larynx preservation protocol.
Design:
Prospective study.
Setting:
Consecutive patients treated in a tertiary cancer center hospital between 2001 and 2002.
Patients:
Eligible subjects included patients prospectively enrolled in an organ preservation protocol based on concomitant radiotherapy and chemotherapy (cisplatin and paclitaxel).
Main Outcome Measures:
Descriptive analysis of the results of audiologic evaluations, including pure-tone audiometry and immitance audiometry, which were performed prior to and 8 months after treatment. Change in hearing sensitivity was computed relative to baseline measures. Criteria to indicate hearing decrease after the treatment were defined as either a 20-dB decrease at any single test frequency or a 10-dB decrease at any 2 adjacent test frequencies.
Results:
A total of 11 patients were analyzed. Four patients (36%) had hearing loss after the treatment.
Conclusion:
Our results suggest that the prevalence of hearing loss after radiochemotherapy in larynx preservation protocols is high (36%); however, it was usually mild and asymptomatic.
